PT  - JOURNAL ARTICLE
AU  - RUBENSTEIN, MARVIN
AU  - HOLLOWELL, COURTNEY M.P.
AU  - GUINAN, PATRICK
TI  - No Compensation in VEGF Expression Follows Antisense Suppression of BCL-2 Activity
DP  - 2012 Nov 01
TA  - In Vivo
PG  - 937--940
VI  - 26
IP  - 6
4099  - http://iv.iiarjournals.org/content/26/6/937.short
4100  - http://iv.iiarjournals.org/content/26/6/937.full
SO  - In Vivo2012 Nov 01; 26
AB  - Antisense oligonucleotides (oligos) have been employed against prostate cancer models targeting growth-regulatory proteins, and at least one oligo (against bcl-2) has reached clinical trial. We previously found that, in LNCaP cells, mono- and bispecific oligos, which comparably suppressed the expression of bcl-2, compensated with suppression of caspase-3 (apoptosis promoter) activity, and enhanced the expression of the androgen receptor (AR) and its p300 and IL-6 co-activators. In addition, prostate-specific membrane antigen (PSMA) and (possibly its regulator) interferon (IFN) were elevated. A total of 14 proteins distributed between regulators of apoptosis, androgen regulation, differentiation antigens and autocrine-mediated growth have previously been examined. We extend these findings to include vascular endothelial growth factor (VEGF), a promoter of angiogenesis, which is not significantly altered through compensation, and therefore would not need additional regulation for suppressive bcl-2 therapy to be effective (like caspase-3).